Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Protagonist Therapeutics (PTGX)

Protagonist swings to Q4 2023 net income of $27.3 million from prior-year loss

Positive Impact 3 of 5 earnings Written later

Protagonist Therapeutics reported fourth-quarter 2023 net income of $27.3 million, or $0.44 per diluted share, compared with a net loss of $34.2 million in the same quarter of 2022. Revenue came from $60 million in JNJ-2113 milestones, while the full-year net loss narrowed to $79.0 million from $127.4 million.

Key points

  • Q4 2023 license and collaboration revenue was $60 million, versus zero in Q4 2022, from milestones tied to JNJ-2113.
  • Full-year 2023 net loss was $79.0 million, or $1.39 per share, compared with $127.4 million, or $2.60 per share, in 2022.
  • Cash, cash equivalents and marketable securities were $341.6 million as of December 31, 2023, up from $237.4 million a year earlier.

The filing

CompanyProtagonist Therapeutics (PTGX)
Form8-K, current report
Filed with the SECFeb 27, 2024, 4:12 PM ET
Accession number0001104659-24-028208

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 27, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.